Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials

BACKGROUND: Sacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert consensus. The cost utility of sacubitril-valsartan for hypertension remains uninvestigated. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Lou, Yake, Yu, Ying, Liu, Jinxing, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9432800/
https://www.ncbi.nlm.nih.gov/pubmed/36062091
http://dx.doi.org/10.3389/fpubh.2022.959139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9432800/
https://www.ncbi.nlm.nih.gov/pubmed/36062091
http://dx.doi.org/10.3389/fpubh.2022.959139

Ejemplares similares